Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Parathyroid Glands00:59

The Parathyroid Glands

The two pairs of parathyroid glands embedded within the posterior surface of the thyroid gland are restricted by a dense capsule around them. These glands comprise two distinct cell populations—parathyroid oxyphil and parathyroid principal cells- pivotal in calcium homeostasis.
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by producing...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Skeleton and Calcium Homeostasis01:21

Skeleton and Calcium Homeostasis

Calcium is not only the most abundant mineral in bone but also the most abundant mineral in the human body. Calcium ions are needed for bone mineralization, tooth health, heart rate regulation and strength of contraction, blood coagulation, the contraction of smooth and skeletal muscle cells, and the regulation of nerve impulse conduction. The average calcium level in the blood is about 10 mg/dL. When the body cannot maintain this level, a person will experience hypo or hypercalcemia.
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacodynamics of sustained levels of PTH following palopegteriparatide treatment in adults with hypoparathyroidism.

Journal of the Endocrine Society·2026
Same author

Increased Prevalence of Coronary Artery Calcification in Patients with Post-Surgical Hypoparathyroidism.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 2-Year Results from the Phase 3 PaTHway-Trial.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Intratrabecular bone remodeling - a previously overlooked mode of remodeling hyperactivated by parathyroid hormone.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Understanding hypoparathyroidism as a disease of broad functional deficiency.

Trends in endocrinology and metabolism: TEM·2026
Same author

Palopegteriparatide for Adults with Chronic Hypoparathyroidism: Skeletal Dynamics Through 3 yr of the Phase 2 paTH Forward Trial.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026

Related Experiment Video

Updated: Jun 2, 2026

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
07:13

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation

Published on: March 14, 2017

PTH treatment in hypoparathyroidism.

Tanja Sikjaer1, Lars Rejnmark, Leif Mosekilde

  • 1Department of Endocrinology and Internal Medicine, Aarhus University Hospital THG, Tage-Hansens Gade 2, DK-8000 Aarhus C, Denmark. tanja.sikjaer@gmail.com

Current Drug Safety
|April 29, 2011
PubMed
Summary

Parathyroid hormone (PTH) therapy shows promise for treating hypoparathyroidism (HypoPT). Clinical trials indicate PTH can stabilize calcium levels, normalize phosphate, and reduce calcium excretion, improving patient quality of life.

More Related Videos

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

Related Experiment Videos

Last Updated: Jun 2, 2026

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
07:13

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation

Published on: March 14, 2017

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

Area of Science:

  • Endocrinology
  • Hormone Replacement Therapy
  • Metabolic Diseases

Background:

  • Hypoparathyroidism (HypoPT) is a rare endocrine disorder characterized by insufficient parathyroid hormone (PTH) production.
  • Traditional HypoPT management relies on calcium and vitamin D supplementation, which can be suboptimal.
  • Historical attempts using bovine PTH were limited by immunogenicity and cost.

Purpose of the Study:

  • To evaluate the efficacy and safety of parathyroid hormone (PTH) replacement therapy in patients with hypoparathyroidism (HypoPT).
  • To assess the impact of PTH treatment on calcium-phosphate balance and urinary calcium excretion.
  • To explore the potential for improved quality of life with PTH therapy compared to conventional treatments.

Main Methods:

  • Review of recent clinical trials investigating PTH (1-34) and PTH (1-84) for HypoPT treatment.
  • Analysis of treatment outcomes including plasma calcium, plasma phosphate, and urinary calcium levels.
  • Comparison of PTH therapy with standard care using 1α-hydroxylated vitamin D metabolites and calcium supplements.

Main Results:

  • PTH (1-34) and PTH (1-84) treatments demonstrated efficacy in stabilizing plasma calcium levels.
  • Normalization of plasma phosphate levels was observed in patients treated with PTH.
  • Reduced urinary calcium excretion and improved patient quality of life were reported with PTH therapy.

Conclusions:

  • Parathyroid hormone (PTH) therapy represents a viable and effective treatment option for hypoparathyroidism (HypoPT).
  • PTH replacement offers advantages over conventional therapy by normalizing key metabolic parameters.
  • Further research and clinical application of PTH drugs like Teriparatide and Preotact are warranted for HypoPT management.